A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

IHC test scores for HER2 status in cancer diagnostics range from 0 to 3+, indicating the amount of HER2 protein overexpression on the surface of cancer cells. 0: No HER2 protein overexpression is ...

HER2 IHC 3+ staining was observed in 15 (4.7%) of the 320 tumor samples analyzed and HER2 IHC 2+ in 26 (8.1%; Table 1). Low HER2 expression (IHC 0 or 1+) was detected in the 279 (87.2% ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Among patients with human epidermal growth factor receptor 2 (HER2, IHC 3+ or IHC 2+/ISH+) positive unresectable and/or metastatic gastric or gastroesophageal cancer, Enhertu (trastuzumab deruxtecan) ...

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the globa ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).